Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK 1 / 2 phosphorylation and p 38 dephosphorylation

Ching-Ting Huang,Ming-Cheng Chang,Yu-Li Chen,Tsung-Ching Chen,Chi-An Chen,W. Cheng
Abstract:Insulin-like growth factors (IGFs) can promote tumorigenesis via inhibiting the apoptosis of cancer cells. The relationship between IGFs and dendritic cell (DC)-mediated immunity were investigated. Advancedstage ovarian carcinoma patients were first evaluated to show higher IGF-1 and IGF-2 concentrations in their ascites than early-stage patients. IGFs could suppress DCs’ maturation, antigen presenting abilities, and the ability to activate antigen-specific CD8+ T cell. IGF-treated DCs also secreted higher concentrations of IL-10 and TNF-α. IGF-treated DCs showed decreased ERK1/2 phosphorylation and reduced p38 dephosphorylation. The percentages of matured DCs in the ascites were significantly lower in the IGF-1 or IGF-2 highly-expressing WF-3 tumor-bearing mice. The IGF1R inhibitor – NVP-AEW541, could block the effects of IGFs to rescue DCs’ maturation and to restore DC-mediated antigen-specific immunity through enhancing ERK1/2 phosphorylation and p38 dephosphorylation. IGFs can inhibit DCmediated anti-tumor immunity through suppressing maturation and function and the IGF1R inhibitor could restore the DC-mediated anti-tumor immunity. Blockade of IGFs could be a potential strategy for cancer immunotherapy. © 2015 Elsevier Ireland Ltd. All rights reserved.
What problem does this paper attempt to address?